Videos and Podcasts

29th Apr 22

Pharmaxis Quarterly Investor Update- 29 April 2022.

Pharmaxis Ltd (ASX: PXS) released its Quarterly Shareholder Update on the morning of 29 April 2022.

Investors and analysts joined the Company for a virtual investor briefing by chief executive officer Mr Gary Phillips.

The event consisted of a short presentation of the Company’s progress over the past quarter and future plans followed by a Q&A session from attendees. You can watch a recording of the presentation here.

1st Apr 22

Pharmaxis R&D Showcase Webinars - Recordings

Pharmaxis Ltd recently hosted R&D Showcase Webinars for each of the Company’s two lead drug discoveries. Presentations by globally renowned clinicians and scientists involved in the Company’s clinical programs were followed by Q&A sessions spearheaded by selected panels of biotech analysts and fund managers. The webinars were moderated by Michael Woods. 

Showcase Webinar #1: Pharmaxis Drug PXS-5505 Targeting Several Cancers. 



Link to recording

Welcome and Introduction to Pharmaxis research and clinical development program

Michael Woods

Dr Wolfgang Jarolimek

Gary Phillips

The myelofibrosis landscape and MF-101

Dr Gabriela Hobbs (Massachusetts General Hospital)

Hepatocellular cancer and Rochester University investigator led study

Dr Paul Burchard (Rochester NY)

Pancreatic Cancer

Dr Tom Cox
(Garvan Sydney) 

Pharmaxis Q&A

Gary Phillips

Panel members: Hashan Da Silva (Karst Peak), Bianca Ogden (Platinum), Dennis Hulme (Taylor Collison) and Derek Jellinek (Morgans)

A pdf of the presentations is available here.

Showcase Webinar #2: Pharmaxis Drug PXS-6302 Designed to Target Skin Scarring.



Link to recording

Welcome and Introduction to Pharmaxis – a global leader in lysyl oxidase chemistry and biology

Gary Phillips

The science of scarring and potential for LOX inhibition

Dr Mark Fear (UWA)

Clinical applications for LOX inhibition

Professor Fiona Wood (UWA)

Q&A with panel

Panel members: Scott Power (Morgan), David Nayagam (Evans and Partners) and Chris Kallos (MST Access)

A pdf of the presentations is available here.

2nd Feb 22

Pharmaxis teams with renowned surgeon Fiona Wood for scar tissue trial

Pharmaxis CEO Gary Phillips speaks to Proactive about the company's phase 1c scar tissue trial, led by world-renowned surgeon Fiona Wood AM. The three-month, placebo-controlled clinical study has already dosed its first patient with Pharmaxis' novel, topical drug treatment for scarring. Fifty patients with established scars will participate in the trial as PXS looks to develop a treatment in a market valued at US$3.5 billion a year.

Watch the interview here